TGA Response: Prohibited Ingredients in E-Cigarettes

Regulations by 2FIRSTS.ai
Jun.21.2023
TGA Response: Prohibited Ingredients in E-Cigarettes
Australian authority fines and issues infringement notices to e-cigarette importers for containing banned ingredients.

The Therapeutic Goods Administration (TGA) in Australia had issued 38 infringement notices and imposed fines totalling AUD 588,840 against four importers of e-cigarettes for violating regulations.

 

The TGA laboratory has found prohibited substances in disposable e-cigarette samples from the brands IGET, GUNNPOD, and HQD, as per the therapeutic goods order for nicotine e-cigarette products (TGO 110) for 2021.

 

In response to the incident, 2FIRSTS promptly conducted an email interview with TGA. On June 21st, TGA Spokesperson replied to 2FIRSTS via email. TGA stated in their response that the disposable e-cigarette products IGET Bar, IGET Legend, GUNNPOD, and HQD were found to contain three prohibited ingredients: benzaldehyde, cinnamaldehyde, and ethylene glycol. According to a search on the TGA official website, (Standard for Nicotine Vaping Products) (TGO 110) Order 2021 specifies the three ingredients are prohibited in e-cigarette products.

 

The following response is from a spokesperson for the Australian Therapeutic Goods Administration.

 

Please attribute the following response to a spokesperson the Therapeutic Goods Administration.

 

1.Is it possible to announce the prohibited ingredients contained in IGET, GUNPOD and HQD branded vapes referenced in the media release?

 

Testing conducted by Therapeutic Goods Administration (TGA) Laboratories identified the IGET Bar and IGET Legend disposable pod devices contained benzaldehyde, cinnamaldehyde and ethylene glycol; Gunnpod disposable pod devices were found to contain benzaldehyde and ethylene glycol; and HQD disposable pod devices were found to contain benzaldehyde, cinnamaldehyde and ethylene glycol.

 

2.Will there be other punishments for the enterprises named, such as arrests? Will the enterprises that produce and manufacture these products also be punished?

 

Infringement notices are one of the compliance tools the TGA can use when we believe that a requirement of the Therapeutic Goods Act 1989 has been breached. If an entity does not pay the infringement notice, the TGA may take further action such as formal court action.

 

The Therapeutic Goods Act 1989 regulates the import, export, supply, manufacture and supply of therapeutic goods within Australia. As the products subject to the infringement notices are manufactured outside of Australia, the manufacturers are not subject to Australian laws.

 

3.Will TGA strengthen supervision in the future?

 

On 2 May 2023, the Minister for Health and Aged Care announced that the Australian Government is taking strong action to combat the supply of unlawful vaping products. The TGA is working closely with state and territory governments and the Australian Border Force to introduce a comprehensive range of reforms, including:

  • stopping the import of non-prescription vapes;
  • increasing the minimum quality standards for vapes including by restricting flavours, colours, and other ingredients;
  • requiring pharmaceutical-like packaging;
  • reducing nicotine concentrations and volumes;
  • banning all single use disposable vapes; and
  • ending vape sales in convenience stores and other retail settings.

 

Note: The previously mentioned "GUNPOD" should be corrected to "GUNNPOD," as stated by TGA in their email reply.

 

Reference(s):

 

Three TSG stores based in Sydney and Jaradat and Sabbagh Group Pty Ltd have been issued with infringement notices totalling $588,840.


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech Launches IKE 2.0 Compliance Platform for Nicotine Products
IKE Tech launched IKE 2.0 on September 28, initially targeting nicotine products with a platform that combines user identity verification, product authentication, configurable policy controls and data analytics. Products can be authenticated through direct device integration or NFC smart tags. IKE Tech was formed with participation from Ispire's Aspire North America, Berify and Chemular, with Ispire currently holding a 40% interest. Its age-verification component PMTA was accepted by the FDA in 2025 and remains under review. The company did not disclose customer names, commercial deployment volumes, pricing or revenue tied to IKE 2.0.
News
Sep.29 by 2Firsts Perspectives
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
Athletes Back Skoka's $21.5 Million Nicotine Pouch Venture: Can Its Consumer Health Founder Make an FDA-Focused Strategy Pay Off?
U.S. nicotine pouch startup Skoka Inc. has raised $21.5 million and committed $15 million to an FDA regulatory and scientific research program. Founder Dan Aziz previously built dietary supplement brand Premama, which was acquired by Dr. Reddy's Laboratories in 2023. Skoka is combining proprietary formulations, ingredient transparency and equity investment from professional athletes. The company submitted a bundled PMTA covering 55 products on October 1, 2026. Aziz said Skoka declined an opportunity to enter retail in 2025, prioritizing product research and regulatory submissions instead. It now targets a U.S. retail launch in 2027, subject to FDA requirements. Its products have not received marketing authorization.
Business
Nov.04
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Special Report|Japan Tobacco Buys CLEW: Can Its 160,000-Store Cigarette Network Help It Vie for U.S. Nicotine Pouch Share Against PMI and BAT?
Japan Tobacco Inc. (JT) announced on November 12, 2026, that it had acquired the U.S. assets of nicotine pouch brand CLEW from Nevcore Innovations Inc., including trademarks, intellectual property, product formulations and a Premarket Tobacco Product Application (PMTA). CLEW, currently distributed through selected outlets in 13 U.S. states, will immediately join the JTI LIGGETT portfolio. The transaction follows JT's approximately $2.4 billion acquisition of U.S. cigarette maker Vector Group in 2024. JTI LIGGETT says its existing cigarette brands reach more than 160,000 U.S. retail stores. During the 2026 NACS Show in October, JTI LIGGETT booth staff told 2Firsts that the company had not yet launched nicotine pouches in the United States. Although Nevcore previously announced FDA acceptance of CLEW's PMTA, the brand is absent from the agency's current list of authorized nicotine pouch products. JT has not disclosed a retail expansion plan for CLEW.
Business
Nov.12
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
Pennsylvania Vape Directory Law Survives Court Challenge From Nova Distro and Others Amid Similar Rulings Across States
Pennsylvania Vape Directory Law Survives Court Challenge From Nova Distro and Others Amid Similar Rulings Across States
A U.S. federal court upheld Pennsylvania's vape directory law on October 14, rejecting a challenge brought by Nova Distro, 101 Distributors and companies operating Tobacco Hut retail stores. Court records show that vaping accounts for about 60% of Tobacco Hut's profits and that the chain held approximately $2 million in inventory potentially subject to seizure under the law as of June 2. Pennsylvania began enforcement on October 19. The ruling follows similar appellate decisions in other states, even as new research shows that unlisted vaping products continue to account for substantial sales in states with established directories.
Regulations
Oct.22